NASDAQ:ALKS - Alkermes Stock Price, Price Target & More

$43.70 -0.67 (-1.51 %)
(As of 04/25/2018 10:36 AM ET)
Previous Close$44.37
Today's Range$43.19 - $44.50
52-Week Range$41.15 - $71.22
Volume184,120 shs
Average Volume1.21 million shs
Market Capitalization$7.00 billion
P/E Ratio-119.92
Dividend YieldN/A
Beta1.82

About Alkermes (NASDAQ:ALKS)

Alkermes logoAlkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes. It is also developing Aripiprazole Lauroxil NanoCrystal Dispersion; ALKS 5461 for the treatment of depressive disorder; ALKS 3831 to treat schizophrenia; BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; and ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; development and license agreement with AstraZeneca plc; and license and collaboration agreement with Biogen MA Inc. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Receive ALKS News and Ratings via Email

Sign-up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ALKS
CUSIPG0176710
Phone353-1772-8000

Debt

Debt-to-Equity Ratio0.23%
Current Ratio2.78%
Quick Ratio2.46%

Price-To-Earnings

Trailing P/E Ratio-119.92
Forward P/E Ratio-76.67
P/E GrowthN/A

Sales & Book Value

Annual Sales$903.37 million
Price / Sales7.50
Cash Flow$0.2667 per share
Price / Cash163.88
Book Value$7.82 per share
Price / Book5.59

Profitability

EPS (Most Recent Fiscal Year)($0.37)
Net Income$-157,940,000.00
Net Margins-17.48%
Return on Equity-4.32%
Return on Assets-2.97%

Miscellaneous

Employees2,000
Outstanding Shares155,000,000

How to Become a New Pot Stock Millionaire

Alkermes (NASDAQ:ALKS) Frequently Asked Questions

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

How were Alkermes' earnings last quarter?

Alkermes (NASDAQ:ALKS) posted its earnings results on Wednesday, February, 14th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.01) by $0.32. The firm had revenue of $275.37 million for the quarter, compared to analyst estimates of $251.23 million. Alkermes had a negative return on equity of 4.32% and a negative net margin of 17.48%. Alkermes's revenue was up 29.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.02 EPS. View Alkermes' Earnings History.

When is Alkermes' next earnings date?

Alkermes is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Alkermes.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes issued an update on its FY18 earnings guidance on Wednesday, February, 14th. The company provided EPS guidance of ($0.23-0.03) for the period, compared to the Thomson Reuters consensus EPS estimate of $0.73. The company issued revenue guidance of $975 million-1.025 billion, compared to the consensus revenue estimate of $1.01 billion.

What price target have analysts set for ALKS?

11 Wall Street analysts have issued 12-month price objectives for Alkermes' shares. Their predictions range from $45.00 to $81.00. On average, they anticipate Alkermes' share price to reach $60.6364 in the next year. View Analyst Ratings for Alkermes.

What are Wall Street analysts saying about Alkermes stock?

Here are some recent quotes from research analysts about Alkermes stock:
  • 1. According to Zacks Investment Research, "Alkermes' Vivitrol and Aristada are primary growth drivers. 2018 is expected to be a transformative year for Alkermes’ development pipeline, with key events being- the phase III data readout for ALKS 3831 in schizophrenia, submission of the BIIB098 (ALKS 8700) NDA and phase I data read-out for ALKS 4230.In April 2018, the FDA accepted for review the new drug application (NDA) for ALKS 5461 for the treatment of major depressive disorder (“MDD”). The FDA had initially issued a Refusal to File letter on Mar 30 for the candidate stating that the NDA did not have enough evidence for the oral medication to work. The company also expects to expand its field sales team by about 200 sales representatives in mid 2018 as it prepares for the potential launch of ALKS 5461 in early 2019. However, Alkermes is highly dependent on manufacturing and/or royalty revenues on sales of products that are commercialized by the company's partners" (4/20/2018)
  • 2. Cantor Fitzgerald analysts commented, "FDA response looks like someone may not have been listening. The nature of the FDA response to ALKS stands in stark contrast to a comment by the CEO on the 2Q17 results conference call, Earlier this week, we passed a major milestone with the outcome of our pre-NDA meeting with the FDA, which resulted in an agreement on our NDA submission content and timing." We generally take with a grain of salt any management comments that FDA meetings went well" or were productive" but we believe investors may have been led to believe that the FDA viewed the ALKS 5461 data as potentially adequate for approval. That the FDA evidently has asked for additional clinical studies strongly calls into question such an assumption, in our opinion." (4/2/2018)
  • 3. Cowen Inc analysts commented, "ALKS reported Q1:17 results which came in below expectations." (4/28/2017)

Who are some of Alkermes' key competitors?

Who are Alkermes' key executives?

Alkermes' management team includes the folowing people:
  • Mr. Richard F. Pops, Chairman & CEO (Age 56)
  • Mr. Shane Martin Cooke, Director (Age 56)
  • Dr. Floyd E. Bloom, Co-Founder & Director (Age 81)
  • Mr. James M. Frates, Sr. VP, CFO & Treasurer (Age 51)
  • Ms. Kathryn L. Biberstein, Chief Admin. Officer, Chief Compliance Officer, Chief Risk Officer & Exec. VP (Age 59)

Has Alkermes been receiving favorable news coverage?

News stories about ALKS stock have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alkermes earned a coverage optimism score of 0.10 on Accern's scale. They also gave media stories about the company an impact score of 44.95 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Alkermes?

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $43.70.

How big of a company is Alkermes?

Alkermes has a market capitalization of $7.00 billion and generates $903.37 million in revenue each year. The company earns $-157,940,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Alkermes employs 2,000 workers across the globe.

How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]


MarketBeat Community Rating for Alkermes (ALKS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  370 (Vote Outperform)
Underperform Votes:  290 (Vote Underperform)
Total Votes:  660
MarketBeat's community ratings are surveys of what our community members think about Alkermes and other stocks. Vote "Outperform" if you believe ALKS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALKS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Alkermes (NASDAQ:ALKS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Alkermes in the last 12 months. Their average twelve-month price target is $60.6364, suggesting that the stock has a possible upside of 38.76%. The high price target for ALKS is $81.00 and the low price target for ALKS is $45.00. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.362.362.452.45
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $60.6364$63.90$63.5455$63.5455
Price Target Upside: 38.76% upside13.00% upside26.18% upside27.47% upside

Alkermes (NASDAQ:ALKS) Consensus Price Target History

Price Target History for Alkermes (NASDAQ:ALKS)

Alkermes (NASDAQ:ALKS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/16/2018Credit Suisse GroupSet Price TargetBuy$63.00MediumView Rating Details
4/3/2018JPMorgan ChaseSet Price TargetBuy$63.00HighView Rating Details
4/2/2018CowenLower Price TargetOutperform$55.00HighView Rating Details
4/2/2018Cantor FitzgeraldLower Price TargetNeutral$45.00HighView Rating Details
2/23/2018Morgan StanleyReiterated RatingOverweight -> Equal Weight$60.00 -> $67.00MediumView Rating Details
2/22/2018Jefferies GroupDowngradeBuy -> Hold$63.19 -> $66.00HighView Rating Details
2/15/2018CitigroupSet Price TargetHold$62.00HighView Rating Details
10/27/2017UBSSet Price TargetHold$57.00 -> $54.00N/AView Rating Details
10/26/2017BarclaysSet Price TargetHold$50.00N/AView Rating Details
10/21/2017MizuhoSet Price TargetBuy$81.00N/AView Rating Details
6/13/2017Leerink SwannDowngradeOutperform -> Market Perform$68.00 -> $61.00MediumView Rating Details
5/26/2016Evercore ISIInitiated CoverageBuy$59.00N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Alkermes (NASDAQ:ALKS) Earnings History and Estimates Chart

Earnings by Quarter for Alkermes (NASDAQ:ALKS)

Alkermes (NASDAQ:ALKS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.35)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.22)($0.22)($0.22)
Q2 20181$0.07$0.07$0.07
Q3 20181($0.12)($0.12)($0.12)
Q4 20181($0.08)($0.08)($0.08)

Alkermes (NASDAQ ALKS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2018($0.08)N/AView Earnings Details
2/14/2018Q4 17($0.01)$0.31$251.23 million$275.37 millionViewListenView Earnings Details
10/26/20179/30/2017($0.01)$0.03$231.29 million$217.40 millionViewN/AView Earnings Details
7/27/20176/30/2017($0.01)$0.01$216.54 million$218.80 millionViewN/AView Earnings Details
4/27/20173/31/2017($0.24)($0.31)$195.79 million$191.80 millionViewN/AView Earnings Details
2/15/2017Q416$0.04$0.15$206.38 million$213.50 millionViewListenView Earnings Details
11/2/2016Q316($0.06)($0.09)$186.39 million$180.20 millionViewListenView Earnings Details
7/28/2016Q216($0.10)($0.01)$174.15 million$195.20 millionViewListenView Earnings Details
4/28/2016Q116($0.20)($0.16)$153.64 million$156.80 millionViewListenView Earnings Details
2/25/2016Q415($0.18)($0.15)$161.24 million$163.10 millionViewListenView Earnings Details
10/29/2015Q315($0.21)($0.18)$151.77 million$152.70 millionViewListenView Earnings Details
7/30/2015Q215($0.10)($0.09)$142.80 million$151.40 millionViewListenView Earnings Details
4/30/2015Q115($0.03)$0.06$146.60 million$161.20 millionViewListenView Earnings Details
2/24/2015Q414$0.04$0.11$161.70 million$175.20 millionViewListenView Earnings Details
10/29/2014Q314($0.12)($0.13)$155.53 million$160.00 millionViewListenView Earnings Details
7/31/2014Q314$0.04($0.01)$146.91 million$153.40 millionViewListenView Earnings Details
4/30/2014Q1$0.10$0.11$135.79 million$130.21 millionViewListenView Earnings Details
2/27/2014Q114$0.20$0.27$142.93 million$154.50 millionViewListenView Earnings Details
10/31/2013$0.22$0.22$137.35 million$139.80 millionViewListenView Earnings Details
7/25/2013Q1 2014$0.22$0.30$131.50 million$138.60 millionViewListenView Earnings Details
5/23/2013Q4 2013$0.17$0.40$128.01 million$163.40 millionViewListenView Earnings Details
1/31/2013Q3 2013$0.23$0.34$130.81 million$135.90 millionViewListenView Earnings Details
11/1/2012Q213$0.11$0.17$121.62 million$124.00 millionViewN/AView Earnings Details
7/26/2012$0.16$0.39ViewN/AView Earnings Details
5/17/2012($0.16)($0.14)ViewN/AView Earnings Details
2/2/2012($0.21)($0.11)ViewN/AView Earnings Details
11/3/2011($0.10)($0.22)ViewN/AView Earnings Details
8/1/2011($0.11)$0.02ViewN/AView Earnings Details
5/18/2011($0.14)($0.14)ViewN/AView Earnings Details
2/3/2011($0.15)($0.06)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.15)($0.08)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.14)($0.14)ViewN/AView Earnings Details
5/13/2010Q1 2010($0.15)($0.15)ViewN/AView Earnings Details
2/4/2010Q4 2009($0.14)($0.07)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.10)($0.09)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.11)($0.11)ViewN/AView Earnings Details
5/21/2009Q1 2009($0.13)($0.14)ViewN/AView Earnings Details
2/5/2009Q4 2008$1.20$1.18ViewN/AView Earnings Details
11/6/2008Q3 2008($0.01)$0.02ViewN/AView Earnings Details
8/7/2008Q2 2008$0.17$0.31ViewN/AView Earnings Details
5/22/2008Q1 2008$0.01($0.07)ViewN/AView Earnings Details
2/7/2008Q4 2007($0.01)($0.02)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Alkermes (NASDAQ:ALKS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Alkermes (NASDAQ ALKS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.51%
Insider Trading History for Alkermes (NASDAQ:ALKS)
Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Alkermes (NASDAQ ALKS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2018Paul J MitchellDirectorSell1,000$46.75$46,750.008,000View SEC Filing  
3/1/2018Paul J MitchellDirectorSell1,000$57.04$57,040.009,000View SEC Filing  
2/16/2018Mark StejbachSVPSell10,880$70.50$767,040.0054,893View SEC Filing  
2/2/2018Shane CookeInsiderSell72,793$60.55$4,407,616.15147,501View SEC Filing  
2/1/2018Paul J MitchellDirectorSell1,000$56.77$56,770.009,000View SEC Filing  
1/29/2018Shane CookeInsiderSell3,300$60.00$198,000.0076,408View SEC Filing  
1/26/2018Shane CookeInsiderSell1,700$60.02$102,034.0076,408View SEC Filing  
1/11/2018Shane CookeInsiderSell6,207$60.22$373,785.5480,915View SEC Filing  
1/2/2018Paul J MitchellDirectorSell1,000$54.99$54,990.009,000View SEC Filing  
12/29/2017Iain Michael BrownSVPSell10,652$54.81$583,836.12View SEC Filing  
12/29/2017Iain Michael BrownCAOSell10,652$54.81$583,836.1216,943View SEC Filing  
12/20/2017Laurie KeatingSVPSell6,249$121.20$757,378.80View SEC Filing  
12/1/2017Paul J MitchellDirectorSell1,000$51.98$51,980.009,000View SEC Filing  
11/29/2017James M FratesSVPSell20,932$50.51$1,057,275.32164,971View SEC Filing  
11/8/2017James M. FratesSVPSell20,932$47.58$995,944.56View SEC Filing  
11/2/2017Richard F PopsDirectorSell50,000$48.87$2,443,500.00View SEC Filing  
11/1/2017Michael J LandineSVPSell15,000$48.71$730,650.00178,693View SEC Filing  
10/2/2017Paul J MitchellDirectorSell1,500$50.64$75,960.00View SEC Filing  
9/11/2017Kathryn L BibersteinCAOSell13,566$51.29$695,800.1470,455View SEC Filing  
9/1/2017Paul J MitchellDirectorSell1,500$50.77$76,155.009,500View SEC Filing  
8/1/2017Paul J MitchellDirectorSell1,500$54.91$82,365.009,500View SEC Filing  
7/3/2017Paul J MitchellDirectorSell1,500$58.11$87,165.009,500View SEC Filing  
6/8/2017Shane CookeInsiderSell10,000$60.33$603,300.0084,708View SEC Filing  
6/1/2017Paul J MitchellDirectorSell1,500$57.49$86,235.009,500View SEC Filing  
5/24/2017Richard F PopsDirectorSell25,000$57.42$1,435,500.00649,137View SEC Filing  
5/18/2017Michael J LandineSVPSell10,000$57.23$572,300.00167,370View SEC Filing  
5/17/2017Richard F PopsDirectorSell50,000$58.19$2,909,500.00680,406View SEC Filing  
5/11/2017Michael J LandineSVPSell10,000$57.01$570,100.00172,370View SEC Filing  
5/10/2017Richard F PopsDirectorSell25,000$57.29$1,432,250.00655,406View SEC Filing  
5/4/2017Shane CookeInsiderSell6,500$60.05$390,325.0078,448View SEC Filing  
4/17/2017Elliot EhrichCMOSell10,000$56.60$566,000.0065,071View SEC Filing  
4/3/2017Kathryn L BibersteinCAOSell15,000$57.68$865,200.0069,904View SEC Filing  
4/3/2017Paul J MitchellDirectorSell1,500$58.31$87,465.009,500View SEC Filing  
3/29/2017Shane CookeInsiderSell2,070$60.00$124,200.0072,148View SEC Filing  
3/23/2017Shane CookeInsiderSell6,030$60.01$361,860.3074,948View SEC Filing  
3/21/2017Shane CookeInsiderSell1,900$60.09$114,171.0072,048View SEC Filing  
3/20/2017Shane CookeInsiderSell300$60.00$18,000.0072,048View SEC Filing  
3/15/2017Elliot EhrichCMOSell11,000$56.74$624,140.0066,071View SEC Filing  
3/7/2017James M FratesSVPSell25,000$59.08$1,477,000.00144,053View SEC Filing  
3/2/2017Robert A BreyerDirectorSell4,000$60.00$240,000.007,156View SEC Filing  
3/2/2017Shane CookeInsiderSell20,000$60.00$1,200,000.0073,068View SEC Filing  
3/1/2017Paul J MitchellDirectorSell1,500$57.06$85,590.009,500View SEC Filing  
2/16/2017Elliot EhrichCMOSell11,000$56.68$623,480.0049,657View SEC Filing  
2/1/2017Paul J MitchellDirectorSell1,500$54.45$81,675.009,500View SEC Filing  
1/17/2017Elliot EhrichCMOSell11,983$54.32$650,916.5662,640View SEC Filing  
1/9/2017Mark StejbachSVPSell547$60.27$32,967.6934,662View SEC Filing  
1/9/2017Shane CookeInsiderSell550$60.27$33,148.5064,494View SEC Filing  
1/6/2017Elliot EhrichCMOSell10,000$59.44$594,400.0060,140View SEC Filing  
1/6/2017Mark StejbachSVPSell9,453$60.05$567,652.6536,615View SEC Filing  
1/6/2017Shane CookeInsiderSell9,450$60.06$567,567.0066,487View SEC Filing  
1/4/2017Robert A BreyerDirectorSell4,000$60.00$240,000.0011,156View SEC Filing  
1/3/2017David Joseph GaffinSVPSell2,500$55.40$138,500.0027,207View SEC Filing  
1/3/2017Paul J MitchellDirectorSell1,500$55.40$83,100.009,500View SEC Filing  
12/16/2016Gordon G PughCOOSell21,458$57.65$1,237,053.7037,277View SEC Filing  
12/15/2016Elliot EhrichCMOSell5,000$55.99$279,950.0057,640View SEC Filing  
12/14/2016James M FratesSVPSell25,000$54.73$1,368,250.00127,342View SEC Filing  
12/12/2016Elliot EhrichCMOSell16,983$55.15$936,612.4564,623View SEC Filing  
12/8/2016Kathryn L BibersteinCAOSell14,145$56.13$793,958.8543,687View SEC Filing  
12/7/2016James M. FratesSVPSell23,731$56.28$1,335,580.68View SEC Filing  
12/1/2016Kathryn L BibersteinCAOSell15,000$56.13$841,950.0038,687View SEC Filing  
11/30/2016Michael J LandineSVPSell10,000$57.51$575,100.00165,659View SEC Filing  
11/29/2016Richard F PopsDirectorSell30,000$56.98$1,709,400.00638,962View SEC Filing  
11/22/2016Richard F PopsDirectorSell30,000$58.66$1,759,800.00638,962View SEC Filing  
10/4/2016Paul J MitchellDirectorSell2,000$47.42$94,840.0010,000View SEC Filing  
9/22/2016Elliot EhrichCMOSell5,000$50.83$254,150.0046,477View SEC Filing  
9/16/2016Elliot EhrichCMOSell5,000$48.87$244,350.0050,311View SEC Filing  
9/6/2016David Joseph GaffinSVPSell2,382$45.92$109,381.4422,816View SEC Filing  
9/6/2016Elliot EhrichCMOSell10,000$46.02$460,200.0055,311View SEC Filing  
9/6/2016Iain Michael BrownCAOSell29,976$45.92$1,376,497.9225,696View SEC Filing  
9/6/2016Paul J MitchellDirectorSell2,000$45.92$91,840.0010,000View SEC Filing  
8/4/2016Paul J MitchellDirectorSell2,000$49.48$98,960.0010,000View SEC Filing  
7/27/2016Elliot EhrichCMOSell35,199$51.95$1,828,588.0546,111View SEC Filing  
7/5/2016Paul J MitchellDirectorSell2,000$45.81$91,620.0010,000View SEC Filing  
6/6/2016Paul J MitchellDirectorSell2,000$44.98$89,960.0010,000View SEC Filing  
5/4/2016Paul J MitchellDirectorSell2,000$38.60$77,200.0010,000View SEC Filing  
4/20/2016Michael J LandineSVPSell16,875$41.09$693,393.75159,419View SEC Filing  
4/19/2016Richard F PopsCEOSell18,750$40.15$752,812.50595,247View SEC Filing  
4/18/2016Iain Michael BrownCAOSell5,368$39.27$210,801.3651,822View SEC Filing  
4/13/2016Elliot EhrichCMOSell11,698$37.66$440,546.6852,642View SEC Filing  
4/12/2016Richard F PopsCEOSell25,000$37.79$944,750.00601,497View SEC Filing  
4/4/2016Paul J MitchellDirectorSell2,000$35.65$71,300.0010,000View SEC Filing  
3/22/2016Richard F PopsCEOSell25,000$31.77$794,250.00601,497View SEC Filing  
3/15/2016Richard F PopsCEOSell25,000$31.40$785,000.00581,307View SEC Filing  
3/4/2016Paul J MitchellDirectorSell2,000$32.80$65,600.0010,000View SEC Filing  
3/3/2016David W AnsticeDirectorBuy5,000$32.87$164,350.0015,000View SEC Filing  
2/4/2016Paul J. MitchellDirectorSell2,000$32.81$65,620.008,000View SEC Filing  
1/4/2016Robert A BreyerDirectorSell2,000$77.33$154,660.0035,156View SEC Filing  
12/28/2015Mark StejbachinsiderSell10,000$80.24$802,400.0019,564View SEC Filing  
12/23/2015Shane CookeinsiderSell18,000$77.23$1,390,140.0050,240View SEC Filing  
12/7/2015Michael J. LandineSVPSell3,750$73.02$273,825.00141,324View SEC Filing  
12/7/2015Richard F. PopsCEOSell37,500$72.06$2,702,250.00553,497View SEC Filing  
12/1/2015Mark StejbachinsiderSell18,000$72.18$1,299,240.0019,564View SEC Filing  
12/1/2015Michael J. LandineSVPSell10,000$72.18$721,800.00141,324View SEC Filing  
12/1/2015Richard F. PopsCEOSell50,000$72.29$3,614,500.00553,497View SEC Filing  
12/1/2015Robert A BreyerDirectorSell2,000$73.46$146,920.0037,156View SEC Filing  
11/23/2015Shane CookeinsiderSell18,000$72.62$1,307,160.0050,240View SEC Filing  
11/2/2015Mark StejbachinsiderSell18,000$72.06$1,297,080.0019,964View SEC Filing  
11/2/2015Robert A BreyerDirectorSell2,000$71.80$143,600.0039,156View SEC Filing  
10/29/2015Iain Michael BrownCAOSell10,822$69.99$757,431.7838,689View SEC Filing  
10/23/2015Shane CookeinsiderSell18,000$62.03$1,116,540.0050,240View SEC Filing  
10/13/2015James M. FratesCFOSell20,000$59.78$1,195,600.0051,357View SEC Filing  
10/2/2015Robert A. BreyerDirectorSell2,000$60.00$120,000.0041,156View SEC Filing  
9/23/2015Shane CookeinsiderSell18,000$67.09$1,207,620.0040,640View SEC Filing  
9/17/2015Michael J. LandineSVPSell10,000$71.20$712,000.00138,680View SEC Filing  
9/17/2015Richard F. PopsCEOSell50,000$71.27$3,563,500.00542,917View SEC Filing  
9/15/2015James M. FratesCFOSell20,000$71.10$1,422,000.0048,713View SEC Filing  
9/10/2015Michael J. LandineSVPSell10,000$67.61$676,100.00138,680View SEC Filing  
9/10/2015Richard F. PopsCEOSell50,000$67.57$3,378,500.00542,917View SEC Filing  
9/1/2015Robert A BreyerDirectorSell2,000$61.43$122,860.0043,156View SEC Filing  
8/24/2015Shane CookeinsiderSell18,000$57.65$1,037,700.0040,640View SEC Filing  
7/23/2015Shane CookeInsiderSell18,000$69.79$1,256,220.00View SEC Filing  
7/20/2015Gordon G PughCOOSell18,750$70.10$1,314,375.00View SEC Filing  
7/14/2015James M FratesCFOSell20,000$65.79$1,315,800.00View SEC Filing  
7/1/2015Gordon G PughCOOSell13,750$65.13$895,537.50View SEC Filing  
7/1/2015Robert A BreyerDirectorSell2,000$64.90$129,800.00View SEC Filing  
6/23/2015Shane CookeInsiderSell18,000$66.84$1,203,120.00View SEC Filing  
6/17/2015Paul J MitchellDirectorSell15,500$65.10$1,009,050.00View SEC Filing  
6/16/2015Gordon G PughCOOSell32,977$63.11$2,081,178.47View SEC Filing  
6/16/2015James M FratesCFOSell10,000$58.63$586,300.00View SEC Filing  
6/1/2015Paul J MitchellDirectorSell1,500$60.78$91,170.00View SEC Filing  
6/1/2015Rebecca PetersonSVPSell21,983$60.05$1,320,079.15View SEC Filing  
5/26/2015Rebecca PetersonSVPSell1,322$60.49$79,967.78View SEC Filing  
5/26/2015Shane CookeInsiderSell18,000$60.31$1,085,580.00View SEC Filing  
5/22/2015Rebecca PetersonSVPSell28,558$61.71$1,762,314.18View SEC Filing  
5/12/2015James M FratesCFOSell10,000$59.34$593,400.00View SEC Filing  
5/4/2015Robert A BreyerDirectorSell2,000$60.00$120,000.00View SEC Filing  
5/1/2015Paul J MitchellDirectorSell1,500$55.79$83,685.00View SEC Filing  
4/23/2015Shane CookeInsiderSell18,000$62.55$1,125,900.00View SEC Filing  
4/21/2015Elliot EhrichCMOSell25,000$62.39$1,559,750.00View SEC Filing  
4/15/2015Gordon G PughCOOSell13,750$63.21$869,137.50View SEC Filing  
4/15/2015James M FratesCFOSell10,000$62.42$624,200.00View SEC Filing  
4/15/2015Paul J MitchellDirectorSell1,500$62.71$94,065.00View SEC Filing  
4/1/2015Robert A BreyerDirectorSell5,000$61.22$306,100.00View SEC Filing  
3/23/2015Shane CookeInsiderSell18,000$65.33$1,175,940.00View SEC Filing  
3/16/2015Elliot EhrichCMOSell18,000$66.81$1,202,580.00View SEC Filing  
3/10/2015James M FratesCFOSell10,000$66.25$662,500.00View SEC Filing  
3/5/2015Rebecca PetersonSVPSell17,737$71.37$1,265,889.69View SEC Filing  
3/2/2015Gordon G PughCOOSell15,000$71.39$1,070,850.00View SEC Filing  
3/2/2015Robert A BreyerDirectorSell5,000$70.86$354,300.00View SEC Filing  
2/23/2015Shane CookeInsiderSell18,000$74.29$1,337,220.00View SEC Filing  
2/17/2015Elliot EhrichCMOSell18,000$70.87$1,275,660.00View SEC Filing  
2/3/2015James M FratesCFOSell10,000$70.83$708,300.00View SEC Filing  
2/2/2015Gordon G PughCOOSell15,000$72.01$1,080,150.00View SEC Filing  
2/2/2015Robert A BreyerDirectorSell5,000$72.91$364,550.00View SEC Filing  
1/26/2015Gordon G PughCOOSell15,000$70.02$1,050,300.00View SEC Filing  
1/23/2015Shane CookeInsiderSell118,000$69.13$8,157,340.00View SEC Filing  
1/16/2015Floyd E BloomDirectorSell20,000$67.12$1,342,400.00View SEC Filing  
1/15/2015Elliot EhrichCMOSell18,375$66.45$1,221,018.75View SEC Filing  
1/15/2015James M FratesCFOSell10,000$66.86$668,600.00View SEC Filing  
1/7/2015Kathryn L BibersteinSVPSell28,374$65.00$1,844,310.00View SEC Filing  
1/2/2015Robert A BreyerDirectorSell5,000$58.57$292,850.00View SEC Filing  
12/11/2014Richard F PopsCEOSell100,000$56.04$5,604,000.00View SEC Filing  
12/10/2014James M FratesCFOSell18,870$56.07$1,058,040.90View SEC Filing  
12/9/2014Michael J LandineSVPSell18,000$56.82$1,022,760.00View SEC Filing  
12/5/2014Kathryn L BibersteinSVPSell15,433$57.61$889,095.13View SEC Filing  
12/1/2014Robert A BreyerDirectorSell5,000$54.64$273,200.00View SEC Filing  
11/19/2014James M FratesCFOSell8,000$53.86$430,880.00View SEC Filing  
11/13/2014Richard F PopsCEOSell100,000$52.87$5,287,000.00View SEC Filing  
11/7/2014James M FratesCFOSell13,303$49.98$664,883.94View SEC Filing  
11/6/2014Kathryn L BibersteinSVPSell20,000$50.54$1,010,800.00View SEC Filing  
11/3/2014Robert A BreyerDirectorSell5,000$50.05$250,250.00View SEC Filing  
10/23/2014Gordon G PughCOOSell14,577$45.00$655,965.00View SEC Filing  
10/8/2014James M FratesCFOSell16,000$41.00$656,000.00View SEC Filing  
10/1/2014Robert A BreyerDirectorSell5,000$42.59$212,950.00View SEC Filing  
9/24/2014James M FratesCFOSell16,000$45.29$724,640.00View SEC Filing  
9/18/2014Michael J LandineSVPSell15,000$45.60$684,000.00View SEC Filing  
9/17/2014Gordon G PughCOOSell14,900$45.04$671,096.00View SEC Filing  
9/17/2014Richard F PopsCEOSell50,000$44.89$2,244,500.00View SEC Filing  
9/10/2014James M FratesCFOSell16,000$43.18$690,880.00View SEC Filing  
9/2/2014Gordon G PughCOOSell1,100$45.08$49,588.00View SEC Filing  
9/2/2014Robert A BreyerDirectorSell5,000$45.12$225,600.00View SEC Filing  
8/27/2014James M FratesCFOSell16,000$45.08$721,280.00View SEC Filing  
8/26/2014Gordon G PughCOOSell16,000$45.00$720,000.00View SEC Filing  
8/13/2014James M FratesCFOSell15,000$41.37$620,550.00View SEC Filing  
8/11/2014Elliot EhrichCMOSell16,667$41.65$694,180.55View SEC Filing  
8/4/2014Gordon G PughCOOSell23,250$43.20$1,004,400.00View SEC Filing  
8/1/2014Robert A BreyerDirectorSell5,000$42.53$212,650.00View SEC Filing  
7/16/2014James M FratesCFOSell8,000$46.50$372,000.00View SEC Filing  
7/9/2014Elliot EhrichCMOSell16,667$47.41$790,182.47View SEC Filing  
7/9/2014James M FratesCFOSell7,000$47.41$331,870.00View SEC Filing  
7/3/2014Michael J LandineSVPSell7,000$51.31$359,170.00View SEC Filing  
7/2/2014Richard F PopsCEOSell50,000$51.69$2,584,500.00View SEC Filing  
7/1/2014Gordon G PughCOOSell16,000$46.49$743,840.00View SEC Filing  
7/1/2014Robert A BreyerDirectorSell5,000$50.57$252,850.00View SEC Filing  
6/26/2014Michael J LandineSVPSell10,000$49.92$499,200.00View SEC Filing  
6/25/2014James M FratesCFOSell7,000$50.22$351,540.00View SEC Filing  
6/25/2014Richard F PopsCEOSell50,000$49.87$2,493,500.00View SEC Filing  
6/20/2014Paul J MitchellDirectorSell17,000$50.00$850,000.00View SEC Filing  
6/19/2014Elliot EhrichCMOSell17,282$47.10$813,982.20View SEC Filing  
6/19/2014Michael J LandineSVPSell10,000$47.01$470,100.00View SEC Filing  
6/18/2014Richard F PopsCEOSell50,000$46.72$2,336,000.00View SEC Filing  
6/17/2014Kathryn L BibersteinSVPSell8,400$47.41$398,244.00View SEC Filing  
6/11/2014James M FratesCFOSell7,000$47.72$334,040.00View SEC Filing  
6/9/2014Elliot EhrichCMOSell16,667$48.15$802,516.05View SEC Filing  
6/2/2014Gordon G PughCOOSell16,000$45.34$725,440.00View SEC Filing  
6/2/2014Robert A BreyerDirectorSell5,000$45.18$225,900.00View SEC Filing  
5/30/2014Rebecca PetersonSVPSell21,981$45.86$1,008,048.66View SEC Filing  
5/23/2014Rebecca PetersonSVPSell1,321$45.08$59,550.68View SEC Filing  
5/22/2014Elliot EhrichCMOSell2,378$44.49$105,797.2220,992View SEC Filing  
5/22/2014Gordon PughCOOSell15,700$45.25$710,425.0054,192View SEC Filing  
5/22/2014Rebecca PetersonSVPSell19,807$44.02$871,904.141,321View SEC Filing  
5/21/2014Elliot EhrichCMOSell1,981$44.00$87,164.0023,370View SEC Filing  
5/21/2014James FratesCFOSell7,000$44.30$310,100.0042,904View SEC Filing  
5/20/2014Rebecca PetersonSVPSell20,307$44.05$894,523.35View SEC Filing  
5/19/2014Elliot EhrichCMOSell2,206$43.55$96,071.3020,992View SEC Filing  
5/8/2014Floyd BloomDirectorSell10,000$46.16$461,600.0090,281View SEC Filing  
5/5/2014Robert BreyerDirectorSell5,000$46.72$233,600.0053,756View SEC Filing  
5/1/2014Paul MitchellDirectorSell1,000$45.90$45,900.008,000View SEC Filing  
4/9/2014James FratesCFOSell7,000$42.91$300,370.0036,644View SEC Filing  
4/1/2014Paul MitchellDirectorSell1,500$44.14$66,210.008,000View SEC Filing  
3/19/2014James FratesCFOSell7,000$46.84$327,880.0036,644View SEC Filing  
3/11/2014Wendy DixonDirectorBuy1,600$47.37$75,792.001,600View SEC Filing  
3/5/2014James FratesCFOSell7,000$47.78$334,460.0093,644View SEC Filing  
2/18/2014Elliot EhrichCMOSell7,718$52.45$404,809.1016,579View SEC Filing  
2/3/2014Paul MitchellDirectorSell1,500$48.15$72,225.008,000View SEC Filing  
1/21/2014Elliot EhrichCMOSell7,718$48.61$375,171.9816,579View SEC Filing  
1/16/2014Elliot EhrichCMOSell14,555$47.35$689,179.2516,579View SEC Filing  
1/16/2014Gordon PughCOOSell30,000$47.16$1,414,800.0048,301View SEC Filing  
1/16/2014James FratesCFOSell7,000$47.40$331,800.0093,644View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Alkermes (NASDAQ ALKS) News Headlines

Source:
DateHeadline
Alkermes ALKS 5461 Moves Closer To CommercializationAlkermes' ALKS 5461 Moves Closer To Commercialization
seekingalpha.com - April 24 at 4:55 PM
Is Alkermes Promising Depression Drug Back On Track?Is Alkermes' Promising Depression Drug Back On Track?
www.fool.com - April 24 at 9:06 AM
Is Alkermes' Promising Depression Drug Back On Track?Is Alkermes' Promising Depression Drug Back On Track?
finance.yahoo.com - April 23 at 4:38 PM
Johnson & Johnson's First-Quarter 2018 Earnings ReviewJohnson & Johnson's First-Quarter 2018 Earnings Review
finance.yahoo.com - April 22 at 5:37 PM
Alkermes (ALKS) Cut to Hold at Zacks Investment ResearchAlkermes (ALKS) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 20 at 11:52 AM
Alkermes Gets Ability To Refile NDA, But All Is Still Not RosyAlkermes Gets Ability To Refile NDA, But All Is Still Not Rosy
seekingalpha.com - April 19 at 4:52 PM
Alkermes to Host Conference Call to Discuss First Quarter 2018 Financial ResultsAlkermes to Host Conference Call to Discuss First Quarter 2018 Financial Results
finance.yahoo.com - April 19 at 4:52 PM
Alkermes Plc (ALKS) Given Average Rating of "Hold" by BrokeragesAlkermes Plc (ALKS) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 19 at 10:15 AM
Alkermes (ALKS) Lifted to Buy at Zacks Investment ResearchAlkermes (ALKS) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - April 18 at 12:50 PM
Wired News – FDA Accepts NDA Review for Alkermes’ ALKS 5461 for Treatment of Major Depressive DisorderWired News – FDA Accepts NDA Review for Alkermes’ ALKS 5461 for Treatment of Major Depressive Disorder
finance.yahoo.com - April 18 at 9:12 AM
Alkermes (ALKS) Scheduled to Post Quarterly Earnings on WednesdayAlkermes (ALKS) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 18 at 3:44 AM
Biotech Analysis Central Pharma News: Mercks Keytruda Breakthrough, Bristol Myers And JNJ Team Up, Alkermes ...Biotech Analysis Central Pharma News: Merck's Keytruda Breakthrough, Bristol Myers And JNJ Team Up, Alkermes ...
seekingalpha.com - April 17 at 5:08 PM
J&J cost cutting plan may pressure suppliers - BloombergJ&J cost cutting plan may pressure suppliers - Bloomberg
seekingalpha.com - April 17 at 9:31 AM
Spotify, Alkermes, Sorrento Therapeutics: Mad Money Lightning RoundSpotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round
www.thestreet.com - April 17 at 9:31 AM
Company News For Apr 17, 2018Company News For Apr 17, 2018
finance.yahoo.com - April 17 at 9:31 AM
Zacks: Analysts Expect Alkermes Plc (ALKS) Will Post Quarterly Sales of $221.82 MillionZacks: Analysts Expect Alkermes Plc (ALKS) Will Post Quarterly Sales of $221.82 Million
www.americanbankingnews.com - April 17 at 5:06 AM
Thinking about buying stock in Alkermes, Bank of America, CVS Health Corp, The Goldman Sachs Group and Tesla ...Thinking about buying stock in Alkermes, Bank of America, CVS Health Corp, The Goldman Sachs Group and Tesla ...
www.prnewswire.com - April 16 at 4:39 PM
Is It Time to Give Up on Alkermes?Is It Time to Give Up on Alkermes?
finance.yahoo.com - April 16 at 4:39 PM
Alkermes Wins Quick Reversal From FDA on Antidepressant DrugAlkermes Wins Quick Reversal From FDA on Antidepressant Drug
finance.yahoo.com - April 16 at 4:39 PM
Credit Suisse Group Analysts Give Alkermes (ALKS) a $63.00 Price TargetCredit Suisse Group Analysts Give Alkermes (ALKS) a $63.00 Price Target
www.americanbankingnews.com - April 16 at 3:37 PM
Alkermes Announces FDA Acceptance for Review of New Drug Application for ALKS 5461 for the Adjunctive Treatment ...Alkermes Announces FDA Acceptance for Review of New Drug Application for ALKS 5461 for the Adjunctive Treatment ...
www.prnewswire.com - April 16 at 9:04 AM
Alkermess stock soars after FDA accepts NDA review, 2 weeks after refusingAlkermes's stock soars after FDA accepts NDA review, 2 weeks after refusing
finance.yahoo.com - April 16 at 9:03 AM
Alkermes Announces FDA Acceptance for Review of New Drug Application for ALKS 5461 for the Adjunctive Treatment of Major Depressive DisorderAlkermes Announces FDA Acceptance for Review of New Drug Application for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder
finance.yahoo.com - April 16 at 9:03 AM
Alkermes (ALKS) Cut to Sell at ValuEngineAlkermes (ALKS) Cut to Sell at ValuEngine
www.americanbankingnews.com - April 15 at 7:48 PM
-$0.08 Earnings Per Share Expected for Alkermes Plc (ALKS) This Quarter-$0.08 Earnings Per Share Expected for Alkermes Plc (ALKS) This Quarter
www.americanbankingnews.com - April 15 at 1:17 AM
Alkermes (ALKS) Cut to Sell at BidaskClubAlkermes (ALKS) Cut to Sell at BidaskClub
www.americanbankingnews.com - April 15 at 12:36 AM
Alkermes (ALKS) Lifted to "Hold" at Zacks Investment ResearchAlkermes (ALKS) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 14 at 10:19 AM
BidaskClub Lowers Alkermes (ALKS) to Strong SellBidaskClub Lowers Alkermes (ALKS) to Strong Sell
www.americanbankingnews.com - April 11 at 10:42 PM
BidaskClub Lowers Alkermes (ALKS) to HoldBidaskClub Lowers Alkermes (ALKS) to Hold
www.americanbankingnews.com - April 11 at 11:30 AM
Alkermes Has Some Decisions to MakeAlkermes Has Some Decisions to Make
finance.yahoo.com - April 11 at 9:45 AM
Alkermes (ALKS) Downgraded by BarclaysAlkermes (ALKS) Downgraded by Barclays
www.americanbankingnews.com - April 7 at 10:53 AM
Alkermes Receives Refusal To File Letter From The FDA, Is There Any Hope?Alkermes Receives Refusal To File Letter From The FDA, Is There Any Hope?
seekingalpha.com - April 6 at 4:56 PM
ValuEngine Downgrades Alkermes (ALKS) to SellValuEngine Downgrades Alkermes (ALKS) to Sell
www.americanbankingnews.com - April 6 at 11:39 AM
FDA Refuses Alkermes Depression Drug Review: 4 Stocks in FocusFDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus
www.zacks.com - April 5 at 9:23 AM
Alkermes Bad News Could Be Good News for Johnson & JohnsonAlkermes' Bad News Could Be Good News for Johnson & Johnson
www.fool.com - April 5 at 9:23 AM
Alkermes Plc (ALKS) Director Sells $46,750.00 in StockAlkermes Plc (ALKS) Director Sells $46,750.00 in Stock
www.americanbankingnews.com - April 4 at 11:37 PM
Alkermes Sees Unusually Large Options Volume (ALKS)Alkermes Sees Unusually Large Options Volume (ALKS)
www.americanbankingnews.com - April 4 at 6:52 AM
Alkermes (ALKS) Stock Rating Lowered by ValuEngineAlkermes (ALKS) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 3 at 8:10 PM
Biotech Analysis Central Pharma News: Takedas Potential Bid, Alkermes Setback, MediciNova ImpressesBiotech Analysis Central Pharma News: Takeda's Potential Bid, Alkermes Setback, MediciNova Impresses
seekingalpha.com - April 3 at 4:44 PM
Alkermes Sinks as FDA Refuses Depression Drug ReviewAlkermes Sinks as FDA Refuses Depression Drug Review
finance.yahoo.com - April 3 at 4:44 PM
JPMorgan Chase Analysts Give Alkermes (ALKS) a $63.00 Price TargetJPMorgan Chase Analysts Give Alkermes (ALKS) a $63.00 Price Target
www.americanbankingnews.com - April 3 at 10:37 AM
Free Research Reports on These Drug Delivery Stocks -- Alkermes, PetMed Express, Valeant Pharma, and Adamis ...Free Research Reports on These Drug Delivery Stocks -- Alkermes, PetMed Express, Valeant Pharma, and Adamis ...
www.prnewswire.com - April 3 at 9:26 AM
Drugmaker Alkermes confirms expansion, hiring plans in WalthamDrugmaker Alkermes confirms expansion, hiring plans in Waltham
www.bizjournals.com - April 3 at 9:26 AM
Alkermes (ALKS) PT Lowered to $55 at CowenAlkermes (ALKS) PT Lowered to $55 at Cowen
www.streetinsider.com - April 2 at 4:43 PM
Brainstorm Health: DNA Testing Accuracy, Marijuana Laws and the Opioid Crisis, Alkermes StockBrainstorm Health: DNA Testing Accuracy, Marijuana Laws and the Opioid Crisis, Alkermes Stock
fortune.com - April 2 at 4:43 PM
Heres Why Alkermes plc and Intra-Cellular Therapies, Inc. Are Crashing TodayHere's Why Alkermes plc and Intra-Cellular Therapies, Inc. Are Crashing Today
www.fool.com - April 2 at 4:43 PM
Alkermes Plunges After FDA Refuses To Review Depression DrugAlkermes Plunges After FDA Refuses To Review Depression Drug
finance.yahoo.com - April 2 at 4:43 PM
Cowen Cuts Alkermes (ALKS) Price Target to $55.00Cowen Cuts Alkermes (ALKS) Price Target to $55.00
www.americanbankingnews.com - April 2 at 4:16 PM
Alkermes (ALKS) Given Outperform Rating at Credit Suisse GroupAlkermes (ALKS) Given Outperform Rating at Credit Suisse Group
www.americanbankingnews.com - April 2 at 1:30 PM
Alkermes (ALKS) Price Target Cut to $45.00Alkermes (ALKS) Price Target Cut to $45.00
www.americanbankingnews.com - April 2 at 1:30 PM

SEC Filings

Alkermes (NASDAQ:ALKS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Alkermes (NASDAQ:ALKS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Alkermes (NASDAQ ALKS) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.